Login / Signup
Phase II Trial of the Impact 0.5% Povidone-Iodine Nasal Spray (Nasodine®) on Shedding of SARS-CoV-2.
Peter L Friedland
Simon Tucker
Published in:
The Laryngoscope (2024)
2 Laryngoscope, 134:3947-3952, 2024.
Keyphrases
</>
sars cov
chronic rhinosinusitis
respiratory syndrome coronavirus
dual energy
open label
placebo controlled
computed tomography
clinical trial
randomized controlled trial
coronavirus disease